October 31st 2024
In an interview with Targeted Oncology, Josep Maria Ribera, MD, PhD, discussed the evolving treatment protocols for Philadelphia chromosome-positive acute lymphoblastic leukemia.
September 24th 2024
Assal Explores the Current Landscape and Future Prospects of BMSCT
January 19th 2024In an interview with Targeted Oncology, Amer Assal, MD, provided insights into the risks and complications associated with stem cell transplants, emphasizing the importance of risk stratification and preventive measures.
Read More
Ruxolitinib Confers Improved Control of Steroid Refractor/Dependent cGVHD
December 11th 2023The 3-year final analysis of efficacy and safety of the REACH3 trial showed that patients with steroid refractory or dependent chronic graft-versus-host disease benefited more with ruxolitinib compared with best available treatment.
Read More
Orca-T Demonstrates High RFS and OS in Intermediate/High-Risk MDS
December 10th 2023Orca-T, an allogeneic hematopoietic cell transplant biologic designed to control alloreactive immune responses, led to less graft-vs-host disease and favorable overall survival and relapse-free survival in patients with intermediate- and high-risk myelodysplastic syndrome.
Read More
Pembrolizumab After ASCT is Feasible in Peripheral T-Cell Lymphoma
November 7th 2023In an interview, Mwanasha Merrill discussed the implication of findings from a phase 2 trial of pembrolizumab after autologous stem cell transplantation for the treatment of patients with peripheral T-cell lymphoma.
Read More
Olaparib With High-Dose Chemo and ASCT Shows Potential in R/R Lymphomas
August 18th 2023In an interview with Targeted Oncology, Yago Nieto, MD, PhD, discussed the implications of findings from the phase 1 study assessing olaparib and high-dose chemotherapy in patients with relapsed/refractory lymphomas.
Read More
Analysis Supports Consolidative Stem Cell Transplant for CD30+ PTCL Post A+CHP
July 25th 2023Though the benefit of consolidative stem cell transplant for patients who received A+CHP appeared less pronounced vs those treated with the CHOP regimen, the method is still supported for patients with CD30-positive peripheral T-cell lymphomas.
Read More
What is Optimal Donor Type for Patients With Cancer in Need of SCT?
May 19th 2023In an interview with Targeted Oncology, Salman Fazal, MD, discussed differences between older matched sibling donors vs younger unrelated donors in stem cell transplants and donor preferences at his institution for patients with cancer.
Read More
Orca-Q Elicits Compelling Data Among Patients Undergoing Haplo HSCT
April 20th 2023In an interview, Samer A. Srour, MD, MS, reviewed data from the dose-expansion phase of an ongoing phase 1 trial of Orca-Q in the haploidentical stem cell transplant setting for patients with high-risk hematologic malignancies.
Read More